BCL2 and Anaplastic (Malignant) Meningioma: The present study demonstrated that navitoclax, an inhibitor of anti-apoptotic BCL-2 family proteins, enhanced the effects of the combination of everolimus and gemcitabine in malignant meningioma cells in vitro and in vivo.